MYC and medulloblastoma: In MEB‐Med‐8A and D283 Med with specific characteristics of the most aggressive c‐myc‐amplified Non‐WNT/Non‐SHH medulloblastoma variant 24, 25, 26, 27, 28, 29, Axitinib reduces viable cell number in a dose‐dependent manner with the highest responsiveness in MEB‐Med‐8A.